ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy...
Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...
Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives of patients with chronic metabolic conditions, including obesity, diabetes, and related diseases, announced the successful completion of an expanded...
UroMems, a global medical technology company developing the first smart automated implant to treat stress urinary incontinence (SUI), today announced the appointment of medical device veteran Rinda Sama to its board of directors. "We are thrilled...
His newly treated patients might show significant improvements on their eye chart tests, but Aaron Nagiel, MD, PhD, will tell you that the truest signs of visual progress come through the texts he receives from parents days, weeks, and months...
BioArctic AB's partner Eisai announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1. Leqembi selectively binds to...
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for...
SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...
Scinai Immunotherapeutics Ltd. a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that Dr. Jonathan Sadeh has...
NS Pharma, Inc. announced a change of leadership within its Commercial division. Effective September 9, 2024, Donald Foy – who had previously served as national sales director – was appointed to the role of vice president, Commercial. Jennifer...
Greifswald-based medical technology pioneer Neoplas Med GmbH is intensifying its strategic collaboration with Niterra Ventures Company, via an $18M capital increase to expand the market further for innovative wound care technology products. With a...
The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...
Animal models expressing loss-of-function mutations in mitochondrial DNA enable the investigation of mitochondrial gene function and related disorders. In a recent study, scientists from Korea University described the impact of a mitochondrial ND5...
Pain. It haunts patients with sickle cell disease (SCD). They live with the looming threat of acute pain crises that could land them in the hospital — where they can struggle to find relief. "A sickle cell disease pain crisis is indescribable. It...
Neurizon Therapeutics Limited a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal...
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova...
Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older...
ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date of June 2, 2025, for its LipidRescue Kit. If...
SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel...
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...
